Patents by Inventor Ralf Anderskewitz

Ralf Anderskewitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120028938
    Abstract: The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L1, L2, X, L3, Y, R1 and R2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.
    Type: Application
    Filed: January 24, 2011
    Publication date: February 2, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten OOST, Ralf ANDERSKEWITZ, Dieter Wolfgang HAMPRECHT, Christoph HOENKE, Domnic MARTYRES, Wolfgang RIST, Peter SEITHER
  • Publication number: 20110021501
    Abstract: The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 may have the meanings given in claim 1, as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.
    Type: Application
    Filed: October 16, 2008
    Publication date: January 27, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Pascale Pouzet, Ralf Anderskewitz, Horst Dollinger, Dennis Fiegen, Thomas Fox, Rolf Goeggel, Christoph Hoenke, Domnic Martyres, Peter Nickolaus, Klaus Klinder
  • Publication number: 20100305102
    Abstract: The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.
    Type: Application
    Filed: October 16, 2008
    Publication date: December 2, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Pascale Pouzet, Ralf Anderskewitz, Horst Dollinger, Dennis Fiegen, Thomas Fox, Rolf Goeggel, Christoph Hoenke, Domnic Martyres, Peter Nickolaus, Klaus Klinder
  • Publication number: 20100190767
    Abstract: Compounds of formula 1 and hetero derivatives thereof and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    Type: Application
    Filed: April 2, 2010
    Publication date: July 29, 2010
    Inventors: Ralf ANDERSKEWITZ, Horst Dollinger, Rolf Goeggel, Birgit Jung, Joerg Kley, Juergen Mack, Peter Nickolaus, Rainer Walter
  • Patent number: 7723381
    Abstract: Compounds of formula 1 and hetero derivatives thereof and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: May 25, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Rolf Goeggel, Birgit Jung, Joerg Kley, Juergen Mack, Peter Nickolaus, Rainer Walter
  • Patent number: 7723360
    Abstract: A compound of general formula 1a wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: May 25, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Domnic Martyres, Franz Birke, Thierry Bouyssou
  • Patent number: 7544806
    Abstract: Accordingly, one object of the present invention are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula 1: wherein R1, R5, R6, A, B, D-E, X-W-V, Y, i, j, n and m are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: June 9, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Patent number: 7214703
    Abstract: Disclosed are compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein the groups Ar1, Ar2, A, R1, R2, R3, E1, E2, X and n are as defined in the description and claims, which are effective modulators of chemokine activity.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: May 8, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Claudia Heine, Pascale Arielle Jane-Josee Pouzet, Thierry Bouyssou, Franz Birke
  • Patent number: 7157471
    Abstract: A compound of general formula 1 wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: January 2, 2007
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Publication number: 20060258861
    Abstract: Compounds of formula 1 and hetero derivatives thereof and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    Type: Application
    Filed: April 21, 2006
    Publication date: November 16, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Rolf Goeggel, Birgit Jung, Joerg Kley, Juergen Mack, Peter Nickolaus, Rainer Walter
  • Publication number: 20060094764
    Abstract: The present invention relates to cyanothiophenes of general formula wherein the Rs are defined as in the claims, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly a glugacon receptor-antagonistic activity.
    Type: Application
    Filed: October 13, 2005
    Publication date: May 4, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Gerd Morschhaeuser, Ruediger Streicher, Thomas Trieselmann, Rainer Walter
  • Publication number: 20060030590
    Abstract: A compound of general formula 1a wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 28, 2005
    Publication date: February 9, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Domnic Martyres, Franz Birke, Thierry Bouyssou
  • Publication number: 20050153979
    Abstract: Accordingly, one object of the present invention are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula 1: wherein R1, R5, R6, A, B, D-E, X—W—V, Y, i, j, n and m are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 16, 2004
    Publication date: July 14, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Publication number: 20050124659
    Abstract: A compound of general formula 1 wherein R1, R5, R6, A, B, Y, i, j and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 23, 2004
    Publication date: June 9, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Dominic Martyres, Pascale Pouzet
  • Patent number: 6861547
    Abstract: The invention relates to a process suitable for large-scale industrial use for preparing compounds of general formula (I) wherein: R1 denotes a group selected from among methyl, ethyl, propyl, cyclopentyl, cyclohexyl, phenyl, benzyl and —C(Me2)phenyl, each of which is optionally mono-, di- or trisubstituted by hydroxy; and, R2 denotes a group selected from among methyl, ethyl, propyl and benzyl.
    Type: Grant
    Filed: May 5, 2002
    Date of Patent: March 1, 2005
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Brandenburg, Rolf Schmid, Rainer Soyka, Ralf Anderskewitz, Rolf Bauer, Rainer Hamm, Jutta Kroeber
  • Patent number: 6855713
    Abstract: The invention concerns benzimidazole derivatives of the general formula (I) in which the radicals R1, R2, R3, X1 and A can have the meanings assigned to them in the specification, their prodrugs, processes for their production as well as the use of the benzimidazole derivatives as medicines, especially as medicines that have trypsin-inhibiting action.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: February 15, 2005
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Pascale Pouzet, Christoph Hoenke, Claudia Heine, Ralf Anderskewitz, Horst Dollinger, Herbert Nar, Hans Michael Jennewein, Bernd Disse
  • Publication number: 20050027122
    Abstract: Disclosed are compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein the groups Ar1, Ar2, A, R1, R2, R3, E1, E2, X and n are as defined in the description and claims, which are effective modulators of chemokine activity.
    Type: Application
    Filed: February 4, 2004
    Publication date: February 3, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Claudia Heine, Pascale Pouzet, Thierry Bouyssou, Franz Birke
  • Publication number: 20050014782
    Abstract: Use of a compound of general formula 1 for manufacturing a medicament to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, in particular compounds of formula 1: wherein R1, R5, R6, A, B, X, W, Z, i, j, k, l and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 8, 2004
    Publication date: January 20, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Franz Birke, Thierry Bouyssou, Horst Dollinger, Domnic Martyres, Pascale Pouzet
  • Patent number: 6780863
    Abstract: Compounds of which the following are exemplary: These have tryptase-inhibiting activity and are useful for the treatment of inflammatory and allergic disease conditions.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: August 24, 2004
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ralf Anderskewitz, Christine Braun, Rainer Hamm, Bernd Disse, Hans Michael Jennewein, Georg Speck
  • Patent number: 6656956
    Abstract: Disclosed are carboxamide-substituted benzimidazole derivatives of general formula (I) wherein the groups X, R1, R2, R3 and R4 may have the meanings given in the claims and specification, processes for preparing them and the use of carboxamide-substituted benzimidazole derivatives as pharmaceutical compositions, particularly as pharmaceutical compositions with a tryptase-inhibiting activity.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: December 2, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Claudia Thies, Christine Braun, Ralf Anderskewitz, Horst Dollinger, Pascale Pouzet, Herbert Nar, Kai Hasselbach, Hans Michael Jennewein, Bernd Disse